These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3552367)

  • 1. Pharmacokinetics and miscibility of 4 highly purified porcine insulins: a study in vitro and in healthy volunteers.
    Heine RJ; Van der Stap H; Salemink PJ; Kolkman-Roodbeen JC; Banken P; Gribnau TC; van der Veen EA
    Diabetes Res; 1987 Jan; 4(1):45-50. PubMed ID: 3552367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption kinetics and action profiles of intermediate acting human insulins.
    Bilo HJ; Heine RJ; Sikkenk AC; van der Meer J; van der Veen EA
    Diabetes Res; 1987 Jan; 4(1):39-43. PubMed ID: 3552366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins.
    Heine RJ; Bilo HJ; Fonk T; van der Veen EA; van der Meer J
    Diabetologia; 1984 Dec; 27(6):558-62. PubMed ID: 6397384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of five pre-mixed combinations of 'short-' and 'intermediate-acting' (NPH) insulins in healthy subjects following subcutaneous administration.
    Owens DR; Jones AL; Dolben J; Dean JD; Petocz P; Coates PA; Luzio SD
    Diabetes Res; 1993; 22(2):77-86. PubMed ID: 8205740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action of a semi-synthetic human insulin preparation (30/70 NPH insulin Organon): comparison with another 30/70 NPH (Actraphane Novo).
    Gin H; Nivet AM; Morlat P; Aubertin J
    Diabete Metab; 1989; 15(5):247-50. PubMed ID: 2698366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Action profile of a semisynthetic human isophane zinc insulin compared with customary isophane insulin].
    Gin H; Delafaye C; Morlat P; Aubertin J
    Diabete Metab; 1992; 18(6):445-50. PubMed ID: 1297601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of subcutaneously administered human, porcine and bovine neutral soluble insulin to normal man.
    Owens DR; Jones MK; Birtwell AJ; Burge CT; Jones IR; Heyburn PJ; Hayes TM; Heding LG
    Horm Metab Res; 1984 Dec; 16 Suppl 1():195-9. PubMed ID: 6152435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate and long-acting insulin preparations without protamine sulphate are complement activators in vitro.
    Duchateau J; Schreyen H; Dorchy H
    Diabete Metab; 1992; 18(4):272-6. PubMed ID: 1459314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the activity and pharmacokinetics of porcine insulin and human insulin (Novo) as assessed by the glucose clamp technique in normal and diabetic man.
    Home PD; Shepherd GA; Noy G; Massi-Benedetti M; Hanning I; Burrin JM; Alberti KG
    Diabetes Care; 1983; 6 Suppl 1():23-8. PubMed ID: 6343033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the activity of Rapitard and Actraphane insulins.
    Colagiuri S; Jones S
    Diabete Metab; 1988 Dec; 14(6):689-92. PubMed ID: 3073090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solubility changes on mixing short- and long-acting insulin preparations.
    Havlik I; Galasko G; Alberts E; Furman KI; Seftel HC
    S Afr Med J; 1988 Mar; 73(6):361-2. PubMed ID: 3281288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative clinical pharmacology of human insulin (Novo) and porcine insulin in normal subjects.
    Ebihara A; Kondo K; Ohashi K; Kosaka K; Kuzuya T; Matsuda A
    Diabetes Care; 1983; 6 Suppl 1():17-22. PubMed ID: 6343032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin.
    Olsson PO; Hans A; Henning VS
    Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of the comparative safety and efficacy of neutral soluble human (semi-synthetic) and porcine monocomponent insulin in non-diabetic subjects.
    Owens DR; Jones MK; Birtwell AJ; Jones IR; Hayes TM; Heding LG; Vølund A; Alberti KG; Home PD
    Diabete Metab; 1982 Jun; 8(2):155-8. PubMed ID: 7049781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical effects of mixing short- and intermediate-acting insulins in the treatment of non-insulin-dependent diabetes.
    Best JD; Ley CJ; Strauss BJ; Alford FP; Aitken PM
    Med J Aust; 1987 Jun; 146(12):621-3, 627. PubMed ID: 3306298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Miscibility of short- and intermediate-acting insulins.
    Heine RJ
    Neth J Med; 1985; 28 Suppl 1():12-4. PubMed ID: 3892332
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of the biological actions and pharmacokinetics of intravenously infused highly purified beef and biosynthetic human insulins in normal man.
    Gray RS; Cowan P; Duncan LJ; Clarke BF
    Diabete Metab; 1984 Sep; 10(3):188-93. PubMed ID: 6386558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin concentrations and time-action profiles of three different intermediate-acting insulin preparations in nondiabetic volunteers under glucose-controlled glucose infusion technique.
    Bottermann P; Gyaram H; Wahl K; Ermler R; Lebender A
    Diabetes Care; 1982; 5 Suppl 2():43-52. PubMed ID: 6765540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of porcine and human isophane (NPH) insulins in normal subjects.
    Owens DR; Jones IR; Birtwell AJ; Burge CT; Luzio S; Davies CJ; Heyburn P; Heding LG
    Diabetologia; 1984 Apr; 26(4):261-5. PubMed ID: 6376233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin.
    Heinemann L; Heise T; Klepper A; Ampudia J; Bender R; Starke AA
    Diabete Metab; 1995 Dec; 21(6):415-9. PubMed ID: 8593922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.